oma cells have been shown to demonstrate morphological changes suggestive of differentiation in response to a variety of substances, including dibutyryl cyclic adenosine monophosphate (dbcAMP), retinoic acid, glial maturation factor, p53 gene transfection, and tumor necrosis factor. 17, 20, 26, 36, 39 It has been reported that when clotrimazole, acting as a potentiation agent, was administered in combination with transretinoic acid, HL-60 cells and acute promyelocytic leukemia cells differentiated into mature granulocytes by increasing migration inhibitory protein-8/14 messenger (m)RNA and decreasing the level of cmyc mRNA. 28 In assessing the differentiation status of glioma cells, analysis of c-myc protooncogene expression is useful, because c-myc is often overexpressed in malignant glial tumors. 9, 24 In glioblastoma and in other cell types, the level of c-myc decreases rapidly with the onset of cellular differentiation. 5, 17, 22, 38 Loss of p53 function arising as a result of gene deletion or mutation is common in cancer cells and occurs in 40 to 60% of glioblastomas. 3, 13, 32 Genetic changes, such as the loss of expression of the p53 tumor suppressor gene, results in failure of apoptosis and acquisition of therapy resistance. The restoration of wild-type p53 function in glioblastoma and other cell types renders the cells more sensitive to irradiation or cisplatin-induced apoptosis. 15, 19 Tumor cells treated with differentiation agents, such as alltransretinoic acid, sodium butyrate, and the calcium-channel blocker nifedipine, can potentiate the cytotoxic effects of cisplatin and other chemotherapeutic drugs. 11, 16, 29 In this study, two established human glioblastoma cell lines, A172 and T98G, in culture were treated with clotrimazole and the effects of clotrimazole on cellular proliferation and structure, expression of GFAP, wild-type p53, and the c-myc and c-fos oncoproteins, and cell cycle distribution were examined. Also evaluated were the effects of mitogenic stimulation with EGF and c-myc on the growth inhibitory effect of clotrimazole. Furthermore, we assessed the cytotoxicity of cisplatin on these cells when combined with clotrimazole. Here, we show that clotrimazole inhibited the growth of glioblastoma cell lines by marked changes in cellular structure and the contents of GFAP, wild-type 53, and the c-myc and c-fos proteins. Finally, we show that clotrimazole enhances the cytotoxic effect of cisplatin by inducing apoptosis.
Materials and Methods

Cell Lines and Culture
Two human glioblastoma cell lines were used in the experiments. The A172 cells have the wild-type p53 allele, whereas T98G cells contain a mutant p53 allele. 37 Both cell lines are routinely maintained in our laboratory. The cells were grown in culture in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin, and gentamycin at 37˚C in a humidified atmosphere of 95% air/5% CO 2 .
In Vitro Cell Proliferation and Morphological Studies
The semiconfluent cells were trypsinized and replated onto 60-mm tissue culture plates (5 ϫ 10 4 cells/plate) or onto 96-well flatbottom culture plates (10 4 cells/well) in DMEM containing 10% FBS. The cells were allowed to attach to the culture plates or wells for 24 hours; subsequently, various concentrations of clotrimazole (dissolved in DMSO as a stock solution) or DMSO alone, used as vehicle, were added and the cells were grown for 72 additional hours. Cell growth was assessed either by performing a direct cell count with the aid of a microscope using a hemocytometer or by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium chloride (MTT) colorimetric assay. The time-dependent growth response of clotrimazole was examined by treating the cells with a dose of 30 M clotrimazole for 72 hours, after which the drug was withdrawn from the culture medium and the cells were incubated for 24 hours longer. At desired time intervals, effects of treatments on cell growth were assayed using the MTT assay. In brief, 10 l of MTT reagent was added to each well and mixed by tapping gently on the sides of the wells; the cells were incubated at 37˚C for 4 hours in the CO 2 incubator until MTT formazan production. The MTT formazan was dissolved in 100 l of isopropanol with 0.04 N HCl in each well. Finally, the absorbances were measured on a microplate reader with a test wavelength of 570 nm and a reference wavelength of 630 nm. The results obtained using either technique for assessing cell growth corresponded with each other. Cellular morphological changes were observed with the aid of a phase-contrast microscope at regular intervals. The effect of clotrimazole on the growth and morphological changes of glioblastoma cells during a long-term (8 days) culture was also studied.
Flow Cytometric Analysis
To determine the effect of clotrimazole on the cell cycle, flow cytometry was used. Untreated and clotrimazole-treated A172 cells were harvested using a 0.1% trypsin/ethylenediaminetetraacetic acid solution and the resultant single-cell suspensions were washed in cold phosphate-buffered saline (PBS) and fixed with 70% ethanol overnight at Ϫ20˚C. The fixed cells were centrifuged (all centrifugations were performed twice at 1000 G for 5 minutes at 4˚C), washed with PBS, and rendered permeable by immersion for 3 minutes in 0.1% Triton-X (1 ml/10 6 cells) on ice. The cells were incubated with ribonuclease (180 U/million cells) for 20 minutes at 37˚C and centrifuged and resuspended at 2 ϫ 10 6 cells/ml of PBS containing propidium iodide (50 g/ml), following which they were incubated overnight in the dark at 4˚C prior to analysis using a flow cytometer.
Western Immunoblot Analysis
To examine the effects of clotrimazole on the cellular expression of GFAP and wild-type p53, c-myc, and c-fos proteins, the cells were treated with 30 M clotrimazole for 72 hours and the cell lysates were examined using Western immunoblot analysis. The untreated and clotrimazole-treated cells were collected by trypsinization and centrifugation (1200 G) for 10 minutes at 4˚C. The cells were resuspended in lysis buffer (10 mM Tris HCl, pH 7.5, 150 mM NaCl, 1 mM MgCl 2 , and 0.5% 1 mM phenylmethylsulfonyl fluoride) for 15 minutes on ice and 15 minutes at room temperature. The proteins in the supernatants, which were obtained following centrifugation, were quantified using a protein assay kit and a spectrophotometer. An equal amount (100 g) of sample protein was loaded onto each lane and electrophoresis was performed using 12% sodium dodecyl sulphate-polyacrylamide gel. The protein was electrophoretically transferred onto nitrocellulose membranes. The membrane containing protein was blocked by storing it in 7% nonfat skimmed milk and 0.1% Tween 20 overnight at 4˚C. After washing, the membranes were incubated with one of the specific antibodies against GFAP, wild-type p53, c-fos, and c-myc for 1 hour at room temperature. After the membranes were incubated with horseradish peroxidase-conjugated secondary antibody, the reactive protein bands were visualized with an enhanced chemiluminescence detection kit. Immunoblots were developed by exposure to xray films.
Serum Starvation and EGF and c-myc Stimulation
In this experiment, A172 and T98G cells were grown in serumfree DMEM for 24 hours, after which they were cultured either in routine culture medium (DMEM and FBS) or in Ca ++ -free DMEM with clotrimazole (30 M) in the presence or absence of exogenous recombinant human EGF (20 ng/ml) and c-myc (20 ng/ml) peptides; cell proliferation was quantified by using the MTT assay.
Inhibition of RNA and Protein Synthesis
To determine whether inhibition of RNA synthesis or protein synthesis results in inhibition of cell growth by clotrimazole, T98G cells were pretreated for 10 minutes with actinomycin D (150 ng/ml) to inhibit RNA synthesis or with cycloheximide (1 g/ml) to inhibit protein synthesis; clotrimazole was then administered. Changes induced in cell growth were quantified using the MTT assay.
In Vitro Cisplatin Cytotoxicity Study
Glioblastoma cells were seeded at 10 4 cells/well (0.1 ml) onto 96-well flat-bottomed plates and incubated overnight at 37˚C. The cells were simultaneously treated with clotrimazole (30 M) and various concentrations of cisplatin continuously for 72 hours, following which cytotoxicity was determined using the MTT assay, as described earlier. The time-dependent responses of the combined treatment of clotrimazole (30 M) and cisplatin (40 M) were also examined using the same method.
The DNA Fragmentation Assay for Apoptosis
We used a DNA fragmentation detection kit in cell preparations fixed on slides. Untreated, clotrimazole-treated (30 M), cisplatintreated (40 M), and combined clotrimazole-cisplatin-treated cells were pelleted by gentle centrifugation and fixed in 4% formaldehyde for 20 minutes. The cells were again centrifuged, resuspended in 80% ethanol, and directly placed onto glass slides. The staining method we used was the same as that directed by the manufacturer. In brief, the fixed cells were permeabilized with proteinase K (1 g/ml) for 10 minutes, peroxidase inactivation was performed by using 3% H 2 O 2 for 5 minutes, and the cells were incubated with equilibration buffer for 30 minutes. The DNA fragment end labeling was performed using a mixture consisting of 68.4 l labeling reaction mix (labeled and unlabeled deoxynucleotide) and 1.6 l enzyme (the large fragment of Escherichia coli DNA polymerase) for 2 hours. The cells were incubated with peroxidase-streptavidin conjugate for 30 minutes and a final reaction was detected by using 3,3Јdiaminobenzidine, counterstained with methyl green, and examined with the aid of a light microscope. A dark-brown 3,3Ј-diaminobenzidine-4 hydrochloride signal indicates positive staining, whereas shades of blue-green to greenish tan signify nonreactive cells. Nonapoptotic cells do not incorporate significant amounts of labeled nucleotide because they lack an excess of the 3Ј-OH ends of the DNA fragment.
Statistical Analysis
The mean values and standard deviations (SDs) were calculated and probability values were obtained using an unpaired Student ttest. A probability value of less than 0.05 was considered to be significant.
Sources of Supplies and Equipment
The two cell lines, A127 and T98G, were obtained from Amer- 
Results
Clotrimazole-Induced Decreases in Proliferation and Increased Differentiation of Glioblastoma Cells
The treatment effects of clotrimazole on the proliferation of A172 and T98G glioblastoma cells were studied. As shown in Fig. 1 , clotrimazole inhibited the growth of glioblastoma cells in a dose-dependent fashion. A concentration of 30M completely blocked cell proliferation in both cell lines with no evidence of apparent toxicity, as assessed by trypan blue dye extraction; however, at concentrations of 50 and 70 M, clotrimazole caused significant cytotoxicity and ultimate cell detachment. For this reason, in the subsequent experiments, a clotrimazole dose of 30 M was used.
The influence of time factor on the proliferation of cells treated by 30 M clotrimazole was studied. Cell growth was almost completely blocked by clotrimazole over a period of 72 hours in treatment (Fig. 2) . After withdrawal of clotrimazole from the culture medium, the cells were cultured for 24 hours more in clotrimazole-free medium, showing that arrested cells again started to proliferate (Fig. 2 , as indicated at 96 hours in culture).
We examined the influence of clotrimazole treatment on cellular morphological changes. As shown in Fig. 3 upper, untreated control T98G cells were characterized by a polygonal shape, wide cell bodies, and few and short cytoplasmic processes. Cells treated with 30 M of clotrimazole for 72 hours showed small retracted cell bodies and thin elongated cytoplasmic processes (Fig. 3 lower) . These changes in cell sizes and shapes were evident as early as at 48 hours of clotrimazole treatment and continued as we observed for 8 days. Cell death began after 3 days of clotrimazole treatment and continued up to our final observation. On Day 8, the clotrimazole was withdrawn and the cells were cultured for 2 more days in clotrimazole-free culture medium. The cultures showed a slow rate in cell growth, no new cells with morphological change, and the previously differentiated cells were still dying. Similar changes were observed in A172 cells (figure not shown) .
Influence of Clotrimazole on the Cell Cycle
To determine the effects of clotrimazole on cell cycle distribution, flow cytometric analysis was performed. As compared with untreated A172 cell cultures, cell cultures treated with clotrimazole for 72 hours displayed an increased accumulation of cells at the G 0 /G 1 -phase and a marked decrease in the number of cells at the S phase; the number of cells at the G 2 /M and G 2 /G 1 cells remained almost unchanged (Fig. 4) . in S-phase cells. Similar effects were seen in clotrimazoletreated T98G cells (data not shown). These findings suggest that clotrimazole inhibited cell proliferation, by arresting the cells in the G 0 /G 1 phase and by decreasing DNA synthesis and that the growth inhibitory effect of clotrimazole is a reversible phenomenon.
Clotrimazole-Induced Increases in GFAP and Wild-Type p53 and Decreases in c-myc and c-fos Protein Expression
We examined the influence of clotrimazole treatment on the cellular expression of GFAP, wild-type p53, c-myc, and c-fos. Western blot analysis (Fig. 5) revealed that, compared with untreated cells, cellular GFAP expression was markedly increased in clotrimazole-treated A172 and T98G glioblastoma cells. In the A172 cell line, which normally expresses wild-type p53, and in the T98G cell line, which is a p53 mutant cell line but does not express wildtype p53, treatment with clotrimazole markedly increased the wild-type p53 level. The same cell lysates were also examined for the mutant p53 protein. The p53 band was not detected in either untreated or clotrimazole-treated A172 cells, whereas the p53 band was detected in both untreated and clotrimazole-treated T98G cells without a remarkable change in the level of expression (data not shown). The levels of c-myc and c-fos oncoproteins were measured in both A172 and T98G cells, revealing that clotrimazole treatment caused a decrease in cellular c-myc and c-fos expression as compared with levels in untreated cells.
Failure of EGF or c-myc Stimulation to Overcome the Growth-Inhibitory Effect of Clotrimazole
Clotrimazole has been shown to inhibit movement of Ca ++ and K + across the plasma membrane and inhibit cell proliferation by depleting [Ca ++ ] i stores and preventing the rise in cytosolic Ca ++ that normally follows after mitogenic stimulation to promote cell growth. 4 We therefore examined the influence of recombinant human EGF and c-myc peptides on the growth inhibitory effect of clotrimazole on preserum-starved A172 and T98G cells simultaneously added to serum culture media. Neither EGF nor c-myc peptide had any influence on the growth inhibitory effect of clotrimazole (Fig. 6 ). Cells grown in Ca ++ -free DMEM were further treated with clotrimazole; no remarkable changes in cell proliferation were observed in clotrimazole-treated cells compared with untreated cells (data not shown).
Inhibition of Cell Growth by Clotrimazole Partially Dependent on RNA and Protein Synthesis
To determine whether cell growth inhibition and apoptosis by clotrimazole are dependent on RNA and protein synthesis, T98G cells were pretreated with actinomycin D or cycloheximide before exposure to clotrimazole. As shown in Fig. 7 , both actinomycin D (0.52 Ϯ 0.08 absorbance unit) and cycloheximide (0.45 Ϯ 0.05 absorbance unit) significantly attenuated clotrimazole-induced growth inhibition (p Ͻ 0.04 and p Ͻ 0.03, respectively). These findings indicate that the decrease in T98G cell growth and viability produced by exposure to clotrimazole partially depends on RNA and protein synthesis. 
Clotrimazole-Induced Enhancement of Cisplatin Cytotoxicity to Glioblastoma Cell Apoptosis
To determine whether clotrimazole synergistically enhances the antitumor activity of cisplatin against A172 and T98G cells, exponentially growing cells were continuously treated with various concentrations of cisplatin (10-70 M) either alone or in combination with clotrimazole (30 M) for 72 hours. As shown in Fig. 8 , cisplatin dose dependently inhibited the growth of A172 and T98G cells. Compared with untreated A172 and T98G cells, cisplatin induced a 50% inhibition of cell growth at 40 and 42 M, respectively. Combined cisplatin-clotrimazole therapy significantly enhanced cytotoxicity in both cell lines. The synergistic effect of clotrimazole was observed at all concentrations of cisplatin that we tested except at 70 M in the A172 cells. As shown in Fig. 9 , the effect of this combined treatment was time dependent with significant synergistic cytotoxicity observed at more than 40 hours posttreatment. Apoptosis was examined in situ in T98G cells subjected to the aforementioned treatments. As demonstrated in Fig. 10 , typical apoptotic cells were detected in cell cultures treated with either clotrimazole or cisplatin alone and the number of apoptic cells were further increased in cell cultures treated by the cisplatin-clotrimazole combination.
Discussion
Clotrimazole inhibits cell proliferation through its downregulatory role in the movements of [Ca ++ ] i and K + . 4 In the present study we showed that, in human glioblastoma cell lines, clotrimazole treatment inhibited cell proliferation, induced morphological changes in cells toward the differentiation state, increased cellular GFAP content and accumulation of wild-type p53 protein, downregulated c-myc and c-fos oncoproteins, increased the number of cells in the G 0 /G 1 phase, and decreased the number of cells in the S phase. The reversible growth-inhibitory effect of clotrimazole was confirmed by the reentry of cells into the cell cycle when clotrimazole was washed out and by the fact that, when cells were further cultured in clotrimazolefree medium, the number of cells in the S phase increased. Our observation suggests that in glioblastomas, clotrimazole inhibits cell proliferation by inhibiting DNA synthesis and by potentiating cellular differentiation-new roles for clotrimazole that have not been studied previously. We also have shown that inhibition of cell growth by clotrimazole partially depends on RNA and protein synthesis, which is supported by a recent observation. 1 The fundamental characteristics of glioblastoma cells are increased heterogeneity and undifferentiated states. A therapeutic strategy is necessary to restrict the proliferation of increasingly divergent glioblastoma cells toward the well-differentiated form. The differentiation status of glial cells is assessed by determining cellular structure and GFAP content. 9, 16, 20 Glial fibrillary acidic protein plays an important role in the maintenance of normal astrocytic structure and regulates the aspect of astrocytic cell growth. 7, 45 The intensity of GFAP staining in glial tumors is inversely related to the degree of anaplasia 21, 24, 30, 46 and the increased expression of GFAP coupled with the morphological changes we observed in the cultured cells
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Clotrimazole in glioblastoma growth and cisplatin cytotoxicity examined here indicates the occurrence of cellular differentiation. 9, 17, 49 Chemically induced differentiation represents an attractive and new component in the multimodality treatment of many tumors. Several brain tumor cell lines have been shown to be responsive to differentiating agents. Cultured glioma cells, when exposed to a variety of substances, including dbcAMP, retinoic acid, glial maturation factor, p53 gene transfection, and tumor necrosis factor, demonstrate morphological changes toward differentiation. 17, 20, 26, 36, 39 Human neuroblastoma and medulloblastoma cell lines have been induced to astrocytic differentiation in the presence of dbcAMP or retinoic acid. 12, 35 One recent report demonstrated, in glioblastoma cells, that butyrate treatment produced a dose-dependent inhibition of cellular proliferation and changes in morphological characteristics, increased GFAP staining, decreased c-myc protein expression, and decreased the number of S-phase cellschanges consistent with a differentiation response. 17 In our study, besides growth inhibition, clotrimazole treatment of glioblastoma cells resulted in increased GFAP expression, decreased c-myc and c-fos protein expression, and a decreased S-phase fraction of cells. These findings suggest that clotrimazole is an effective differentiation agent for glioblastoma.
In addition to examining GFAP expression, an analysis of p53 and c-myc and c-fos oncoprotein expression in glioblastoma is useful, because these proteins participate in cellular differentiation. Loss of p53 function arising as a result of gene deletion or mutation has been described in 40 to 60% of human glioblastomas. 3, 13, 32 Wild-type p53 inhibits cell proliferation and restoration of wild-type p53 elicits dramatic morphological changes in human glioma cell lines in vitro. 33 In our study, we have shown that, after clotrimazole treatment, wild-type p53 is increased not only in the wild-type p53-expressing A172 cell line, but also in the T98G cell line, which is a known mutant p53 cell line. The c-myc oncoprotein is often overexpressed in malignant glial tumors and glioma cell lines 18, 23 and suppression of c-myc expression inhibits proliferation of glioma cells. 8 In glioblastoma and other cell types, the level of c-myc decreases rapidly with the onset of cellular differentiation. 5, 17, 22, 38 In our study, clotrimazole treatment downregulated the c-myc oncoprotein in both A172 and T98G glioblastomas during their differentiation processes. Kizaki, et al., 28 have reported that clotrimazole, when given in combination with retinoic acid, markedly inhibited cellular proliferation and retinoic acid-resistant HL-60 and acute promyelocytic leukemia cells differentiated to mature granulocytes. When retinoic acid was used alone it failed to demonstrate such effects. This combination treatment also resulted in a decreased level of c-myc mRNA. 28 Other early genes such as c-fos are highly expressed in proliferating cells and downregulated when cells switch to differentiation. 31 In our study, clotrimazole-treated cells showed decreased expression of the c-fos protein. Our findings suggest that clotrimazole is an effective differentiation agent, capable of well differentiating the increasingly divergent undifferentiated malignant tumors such as glioblastoma multiforme. The reversible growth inhibitory effect of clotrimazole in glioblastoma cell lines can be explained because the structural genes are still functional, but the response to normal regulators of differentiation is somehow modified.
Binding of growth factors to specific receptors in growth-arrested cells triggers an array of ionic signals, such as an increase in cytosolic Ca ++ released from intracellular stores, capacitative Ca ++ influx through the plasma membrane, and activation of Ca ++ -dependent K + channels in the plasma membrane, which are crucial in the cascade of mitogenic events, eventually leading to DNA synthesis. 34, 42, 43, 48 These mitogen-induced early ionic changes, considered critical events in the signal-transduction pathways, are potential therapeutic targets for inhibition of proliferation of malignant cells. The inhibition of cell proliferation by clotrimazole is due to its capacity to deplete the [Ca ++ ] i stores and to prevent the rise in cytosolic Ca ++ that normally follows after mitogenic stimulation. Preincubation of quiescent Swiss 3T3 cells with clotrimazole while being stimulated by EGF, basic fibroblast growth factor, platelet-derived growth factor, and bradykinin resulted in an almost complete block of the increase in cytosolic free Ca ++ even in the presence of excess extracellular Ca ++ . 4 In our study, when serum-starved A172 and T98G glioblastoma cells were exposed to clotrimazole and simultaneously stimulated with EGF and c-myc, the growth-inhibitory effect of clotrimazole could not be overcome by EGF or c-myc. Thus, clotrimazole can compete with the specific growth factor receptors in the plasma membrane and may interfere with the mitogenic pathways located downstream of the growth factor-receptor interaction. From our experiment, the mechanism by which clotrimazole blocked the cell growth-stimulatory effect of c-myc cannot be explained properly, but it may be that clotrimazole competes with c-myc at the latter's binding sites.
Genetic changes such as a loss of expression of the p53 tumor suppressor gene can result in failure of apoptosis and acquisition of therapy resistance. Stabilization and accumulation of the p53 protein constitute one of the earliest cellular responses to DNA damage. 27 One of the key modulators of apoptosis in cells that have sustained DNA damage is p53 nuclear phosphorylation. 14, 25, 33 Loss of p53 function, arising as a result of gene deletion or mutation, is common in cancer cells and occurs in 35 to 60% of cases of glioblastoma multiforme. 3, 13, 32 Restoration of wild-type p53 function in glioblastoma and other cell types renders the cells more sensitive to irradiation or cisplatin-induced apoptosis. 15, 19 By using p53-expressing adenovirus to directly evaluate the effect of p53 on sensitivity to anticancer drugs including cisplatin, previous studies have demonstrated that exogenous wild-type p53 accelerates cell death induced by DNA-damaging agents in cancer cells. 6, 41 Modification of tumor cells with wildtype human p53, followed by treatment with cisplatin in vivo, significantly prolonged the survival of rats bearing the intracranial 9L glioma when compared with the effect of either treatment alone. 15 In our study, we showed that clotrimazole induced wild-type p53 in A172 cells, which have wild-type p53, and T98G cells, which have mutant p53. 37 We thus assumed that this highly expressed wildtype p53 could be involved in the increased sensitivity of cisplatin. Here, we confirmed that clotrimazole-treated cells were highly sensitive to cisplatin. The exact molecular pathway of apoptosis induced by clotrimazole is still unknown, but when administered as a combined therapy with cisplatin, clotrimazole markedly enhanced cell cytotoxicity and apoptosis, suggesting that induced wild-type p53 is responsible for increased cisplatin cytotoxicity and apoptosis. Other calcium-channel blockers such as nifedipine also enhanced cisplatin cytotoxicity in human glioblastoma cells by inducing apoptosis, 29 but these failed to inhibit cell growth. 4 Studies are now underway in our laboratory to examine the effects of clotrimazole on tumor angiogenesis, cisplatin permeability through the bloodbrain barrier, and cisplatin cytotoxicity in both in vitro and in vivo models.
Conclusions
The present study suggests that clotrimazole is an effective agent to inhibit cell proliferation accompanied by cellular morphological changes toward well-differentiated forms. Clotrimazole also modulates glioblastoma cell growth by inducing GFAP and wild-type p53 (even in the cell line with mutant p53), downregulating the c-myc and c-fos oncoproteins, and inducing apoptosis. Synergistically, clotrimazole enhances the cytotoxic effect of cisplatin. Clotrimazole may be a potentially useful anticancer drug in treating human glioblastoma multiforme. Its potential warrants more study.
